Prometrium and Rivaroxaban Interaction

Why This Interaction Matters Clinically

Women on rivaroxaban for atrial fibrillation, prior VTE, or mechanical prophylaxis sometimes need Prometrium for endometrial protection during hormone replacement therapy. The clinical question is straightforward: does adding micronized progesterone change rivaroxaban's efficacy or safety profile? Two separate mechanisms create concern, one pharmacokinetic and one pharmacodynamic, and each deserves its own risk calculation.

The Patient Population at the Intersection

Postmenopausal women represent the primary overlap group. Atrial fibrillation prevalence rises sharply after age 60, and the same demographic frequently initiates HRT for vasomotor symptoms or bone protection [1]. The Endocrine Society's 2022 position statement supports HRT initiation within 10 years of menopause onset for symptomatic women without contraindications [2]. When a woman in this window also carries an indication for anticoagulation, her prescriber faces a dual-agent scenario with limited direct trial data.

Why Both Drugs End Up on the Same Med List

Rivaroxaban is the most prescribed direct oral anticoagulant (DOAC) in the United States, with over 30 million U.S. Prescriptions dispensed in 2023 [3]. Prometrium (oral micronized progesterone, 100 mg or 200 mg) is the guideline-preferred progestogen for endometrial protection in women with an intact uterus receiving estrogen therapy [4]. The intersection is not rare. It is predictable.

Pharmacokinetic Overlap: CYP3A4 and P-glycoprotein

Rivaroxaban undergoes approximately 18% of its biotransformation through CYP3A4, with additional contributions from CYP2J2 and hydrolysis pathways [5]. It is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). The FDA label for rivaroxaban explicitly warns against co-administration with drugs that are combined strong CYP3A4 and P-gp inhibitors (ketoconazole, ritonavir, itraconazole) because these can increase rivaroxaban AUC by up to 160% [5].

Where Prometrium Fits in This Pathway

Micronized progesterone is metabolized primarily by CYP3A4 to its active metabolite 5-alpha-pregnanolone and other reduced metabolites [6]. Progesterone does not act as a strong CYP3A4 inhibitor. In vitro data classify it as a weak inhibitor at best, with IC50 values well above therapeutic plasma concentrations [7]. It has no established P-gp inhibitory activity at clinical doses.

Net Pharmacokinetic Effect

Because Prometrium is a weak CYP3A4 substrate rather than a potent inhibitor, it is unlikely to raise rivaroxaban plasma levels meaningfully. Competition for the same enzyme could theoretically slow clearance of one or both drugs, but the clinical magnitude of this effect at standard Prometrium doses (100 to 200 mg daily) is estimated to be below the threshold that alters rivaroxaban's anticoagulant response [5][7]. No published pharmacokinetic interaction study has directly measured rivaroxaban exposure changes during co-administration with oral micronized progesterone.

This contrasts sharply with the interaction profile of combined oral contraceptives containing ethinyl estradiol plus synthetic progestins (norethindrone, levonorgestrel), which have more potent effects on hepatic CYP activity and clotting factor synthesis [8].

Pharmacodynamic Concern: VTE Risk Stacking

The pharmacodynamic dimension is more clinically significant than the pharmacokinetic one. Any exogenous hormone with progestogenic activity carries a theoretical VTE signal, and this signal works in direct opposition to the purpose of anticoagulation.

What the Evidence Shows About Progesterone and Clotting

The E3N French cohort study (N=80,308 postmenopausal women) found that transdermal estradiol combined with oral micronized progesterone carried no statistically significant increase in VTE risk compared to non-users (OR 0.9, 95% CI 0.6 to 1.5) [9]. This contrasts with norpregnane-derived synthetic progestins, which showed an OR of 3.9 (95% CI 1.5 to 10.0) in the same cohort [9]. The WHI trial, which used conjugated equine estrogens plus medroxyprogesterone acetate (not micronized progesterone), reported a VTE hazard ratio of 2.06 (95% CI 1.57 to 2.70) [10].

Micronized Progesterone Is Not MPA

This distinction matters. Micronized progesterone has a different receptor binding profile, shorter half-life, and less potent effects on hepatic globulin synthesis compared to medroxyprogesterone acetate [11]. The ESTHER case-control study (N=881 VTE cases and 2,682 controls) confirmed that oral micronized progesterone did not significantly increase VTE risk (OR 0.7, 95% CI 0.3 to 1.9), while synthetic progestins raised it substantially [12].

Clinical Implication for the Rivaroxaban Patient

A woman already anticoagulated with rivaroxaban has a managed thrombotic risk. Adding a hormone with a near-neutral VTE profile (micronized progesterone) does not dramatically alter that equation. The residual concern is not about a large absolute risk increase but about whether any additional prothrombotic signal, however small, could partially offset anticoagulant benefit in a high-risk patient. This is a clinical judgment call, not a hard contraindication.

Severity Classification Across DDI Databases

Drug interaction databases do not uniformly classify this pair. The variation reflects genuine uncertainty.

Database-by-Database Breakdown

Lexicomp rates the interaction between progesterone and rivaroxaban as "Monitor Therapy" (Category C), based on the general class effect of hormonal agents on VTE risk rather than a specific pharmacokinetic interaction [13]. Micromedex does not list a direct monograph for this pair. The FDA label for rivaroxaban does not mention progesterone by name; it warns against strong dual CYP3A4/P-gp inhibitors, which micronized progesterone is not [5].

How to Interpret "Monitor Therapy"

A Category C rating means the combination can be used with appropriate monitoring. It does not mean the drugs should be avoided. Prescribers should document the rationale for concurrent use, confirm the patient understands the theoretical risk, and schedule follow-up assessments at defined intervals.

Monitoring Recommendations When Co-Prescribing

Routine coagulation monitoring is not standard for rivaroxaban monotherapy because DOACs have predictable pharmacokinetics. Adding Prometrium does not change this general principle, but it does warrant a structured clinical surveillance plan.

Laboratory Considerations

Anti-factor Xa levels calibrated to rivaroxaban can confirm drug exposure if there is clinical concern about under- or over-anticoagulation [14]. Standard PT/INR is not reliable for DOAC monitoring. CBC with platelet count should be checked at baseline and every 6 months to detect occult bleeding. Renal function (eGFR) matters because rivaroxaban clearance is partially renal; progesterone does not affect renal function, but age-related decline in the postmenopausal population may shift rivaroxaban exposure over time [5].

Clinical Surveillance

Symptom-based monitoring is the primary tool. Patients should be counseled to report any of the following without delay: new or worsening leg edema, calf pain, chest pain, dyspnea, hemoptysis, prolonged or heavy menstrual bleeding (if still cycling), unusual bruising, dark or bloody stool, or blood in urine. A structured 3-month follow-up after initiating the combination, followed by 6-month intervals, is a reasonable clinical framework.

When to Consider Dose Adjustment

Dose adjustment of either drug is not routinely required. If a patient shows signs of supratherapeutic anticoagulation (unexplained bleeding, elevated anti-Xa trough levels), the Prometrium interaction should be considered in the differential, but other causes (renal impairment, new interacting medications, dietary changes) are more likely contributors.

Prescribing Considerations by Clinical Scenario

Not all patients taking both drugs carry the same risk. The clinical context shapes the approach.

Scenario 1: VTE Prophylaxis After a Single Provoked Event

A woman on rivaroxaban for a time-limited course (3 to 6 months) after a provoked DVT who also needs HRT is at lower risk than a patient on indefinite anticoagulation. Short-term overlap may be acceptable with standard monitoring.

Scenario 2: Atrial Fibrillation on Long-Term Rivaroxaban

This patient is on indefinite anticoagulation. The CHA2DS2-VASc score and HAS-BLED score should be recalculated before adding any agent with thrombotic potential [15]. If the HAS-BLED score is 3 or higher, the risk-benefit ratio of adding any HRT component warrants a documented shared decision-making conversation.

Scenario 3: Mechanical Heart Valve

Rivaroxaban is not approved for mechanical heart valve prophylaxis following the RE-ALIGN trial results with dabigatran [16]. If a patient with a mechanical valve is on warfarin (not rivaroxaban), the interaction profile differs substantially, and this article's guidance does not apply to that scenario.

How Prometrium Compares to Other Progestogens in This Context

The choice of progestogen matters more than the choice of estrogen route when the goal is minimizing VTE risk in an anticoagulated patient.

Safest Options

Oral micronized progesterone (Prometrium) and dydrogesterone carry the lowest VTE signals among available progestogens [9][12]. Transdermal estradiol paired with one of these two agents represents the HRT regimen with the smallest measurable prothrombotic effect.

Higher-Risk Alternatives

Medroxyprogesterone acetate (Provera), norethisterone acetate, and levonorgestrel-releasing IUDs (for systemic progestogenic effect) have varying VTE risk profiles. MPA, used in the WHI, showed the highest signal [10]. The levonorgestrel IUD delivers progesterone locally with minimal systemic absorption; its VTE risk in postmenopausal women has not been directly studied in a large trial.

Clinical Bottom Line on Progestogen Selection

If an anticoagulated woman needs endometrial protection, micronized progesterone is the evidence-supported first choice based on available observational data [9][12]. Switching from Prometrium to a synthetic progestin to "avoid an interaction" would be clinically counterproductive, since synthetic progestins carry higher VTE risk and equal or greater CYP3A4 involvement.

Patient Counseling Points

Clear communication reduces adverse events. Five specific messages should reach the patient before discharge or at the prescribing visit.

What to Tell the Patient

First, both medications can be taken together, but the combination requires monitoring. Second, report any unusual bleeding, including heavier periods, nosebleeds lasting more than 10 minutes, blood in urine or stool, or bruising without clear cause. Third, do not start or stop any new medication (including over-the-counter supplements like St. John's wort, a potent CYP3A4 inducer) without informing the prescribing clinician [5]. Fourth, grapefruit juice inhibits CYP3A4 and can modestly raise levels of both drugs; consistent avoidance or consistent moderate intake is preferable to erratic consumption [17]. Fifth, carry a medical alert card or wear identification indicating anticoagulant use.

FDA Label Highlights for Both Drugs

The rivaroxaban (Xarelto) prescribing information, revised January 2024, lists strong CYP3A4/P-gp inhibitors and inducers as the primary pharmacokinetic interaction concern [5]. The Prometrium prescribing information notes CYP3A4-mediated metabolism and warns about VTE risk as a class effect of progestational agents, with the caveat that micronized progesterone data are more reassuring than synthetic progestin data [6].

Neither FDA label specifically names the other drug as a contraindication or a "do not co-prescribe" warning. The interaction is managed through clinical judgment, not a regulatory prohibition.

The baseline anti-Xa trough level for rivaroxaban 20 mg once daily ranges from 12 to 137 ng/mL, with a median of approximately 44 ng/mL [14]. Any level above 137 ng/mL in a patient taking both drugs should prompt investigation of contributing factors, including new interacting medications, renal function changes, or hepatic impairment.